With ongoing inflation, economic uncertainty, and global tensions, more investors are looking for ways to protect their money while still earning steady returns. Defensive stocks have historically provided such resilience. These stocks, characterized by their stability and ability to generate consistent returns, offer an attractive investment strategy during periods of market turbulence. They typically belong to sectors such as consumer staples, telecom, healthcare, and utilities which are the industries that maintain steady demand regardless of economic conditions. As investors seek ways to protect their portfolios from downturns, defensive stocks emerge as a crucial component of a well-balanced investment strategy.
That said, the investing landscape has evolved dramatically over the last two decades and the well-known defensive sectors are not as defensive as they used to be. To make this point clear, we refer to a March report by investment management firm T. Rowe Price where investment experts discussed portfolio construction and the sectors likely to outperform during a broad market downturn. They highlighted consumer staples, health care, and utilities as potential defensive plays. Adam Marden, one of the T. Rowe Price experts, emphasized health care’s strength, citing long-term demographic trends, a favourable cyclical outlook in health care tools, and biotech’s improving industry structure.
Adam also noted that while utilities remain defensive, rising AI-related power demands have led to speculative valuations, reducing their diversification benefits in an inflation-driven sell-off. Consumer staples can provide stability in various conditions, but historically, they have been most effective when trading at a discount to the broader market. So, while these sectors still offer defensive characteristics, investors should be careful to assess valuations and market conditions before making decisions on buying such stocks or constructing defensive portfolios.
Balancing Stability and Growth
Given the evolving nature of defensive sectors, investors need a more nuanced approach. One such approach focuses on low-volatility stocks, as highlighted by Fidelity Investments. The firm recently highlighted that stocks with lower volatility tend to decline less during market downturns compared to lower-quality stocks. While adding such stocks to a portfolio may help cushion losses in turbulent markets, it can also lead to more moderate gains in strong markets. Though lower-volatility portfolios reduce downside risk, they don’t eliminate it. Historically, portfolios optimized for risk-adjusted returns have delivered higher long-term gains but with greater fluctuations. One way to build a more defensive portfolio is by focusing on stocks with a history of stability, often due to industry positioning, competitive strength, or solid financials. These stocks can help mitigate losses during market selloffs.
Amid this evolving market environment, experts stress the importance of defensive positioning. In a March 15 interview with CNBC, Adam Parker, CEO and founder of Trivariate Research, emphasized that market positioning and expectations are currently misaligned in the market. While many investors have turned bearish, he believes there hasn’t been enough of a positioning shakeout to justify turning bullish just yet. He emphasized that companies’ upcoming earnings guidance will be crucial. If companies lower forecasts and stock prices remain resilient, it could indicate a buying opportunity. He highlighted the importance of playing more defense than offense until market conditions clarify.
Conclusion
Defensive stocks indeed play a critical role in investor portfolios, particularly during volatile market environments. While they may underperform in strong bull markets, their ability to provide stability and mitigate downside risk makes them a valuable asset for long-term investors. By focusing on companies with consistent earnings, strong financials, and a history of resilience, investors can navigate market uncertainties more effectively.
A trader working diligently at her desk, evaluating stocks of multiple industries.
Our Methodology
To determine the 15 best defensive stocks, we began by filtering U.S.-listed companies with a market capitalization exceeding $2 billion across four key defensive sectors: consumer staples, healthcare, utilities, residential real estate, pharmaceuticals, and telecom. Next, we applied three main selection criteria: a beta of less than 1, positive EPS growth over the past three years and the upcoming financial year, and a dividend yield above 1%. From the resulting list, we identified the top 10 stocks with the highest hedge fund ownership, using data from Insider Monkey’s Q4 2024 hedge fund database. Finally, we ranked these stocks in ascending order based on the number of hedge funds holding positions in them.
Note: All pricing data is as of market close on March 21.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
15 Best Defensive Stocks Amid Market Volatility
15. Atmos Energy Corp. (NYSE:ATO)
Beta: 0.67
Number of Hedge Fund Holders: 31
Atmos Energy Corp. (NYSE:ATO) is the first company on our list. Utilities are recognized for their strong defensive traits, including stable businesses and reliable dividend yields. This company is one of the largest fully regulated natural gas utilities in the United States, serving approximately 3.5 million customers across eight states. It is involved in regulated natural gas distribution as well as pipeline and storage operations.
Over the past eleven years, Atmos Energy Corp. (NYSE:ATO) has invested more than $15 billion to upgrade and expand its natural gas infrastructure. These investments include replacing 900 miles of distribution and transmission main lines to improve system reliability and safety. According to the company, 90% of its yearly capital spending generates returns within six months, making it an attractive investment prospect. As of Q1 FY 2025, the company has a weighted average debt maturity of 17.8 years, ensuring financial stability to support its ongoing infrastructure projects. This extended debt maturity reduces short-term refinancing risks while enabling continued investment in modernization efforts.
Mizuho Securities analyst Gabe Moreen recently reaffirmed a Buy rating for Atmos Energy Corp. (NYSE:ATO) following its Q1 2025 earnings report released on February 5. The company slightly exceeded market expectations for earnings per share, further solidifying its consistent performance track record.
The analyst also highlighted the company’s dependable execution and ambitious five-year growth plan, backed by a notable rise in capital expenditures. Additionally, favourable natural gas basis spreads in Texas have contributed positively to its financial outcomes. Although Moody’s has issued a negative credit outlook citing debt levels, Atmos management expects this to be reconsidered.
14. Equity LifeStyle Properties Inc. (NYSE:ELS)
Beta: 0.78
Number of Hedge Fund Holders: 32
Equity LifeStyle Properties Inc. (NYSE:ELS) is a real estate investment trust (REIT) specializing in manufactured home communities, resort-style recreational vehicle (RV) parks, and marinas across North America. With a portfolio of over 450 properties and 173,000 sites, the company benefits from strong demand for affordable housing and leisure-focused properties.
The company operates in a niche area of real estate that has shown resilience during economic cycles, providing steady rental income and consistent returns for shareholders. Its properties generally attract retirees, vacationing families, second homeowners, and first-time homebuyers by offering a community experience and a cost-effective alternative to traditional homeownership.
On January 28, Equity LifeStyle Properties Inc. (NYSE:ELS) announced its Q4 2024 results, which were mostly in line with market expectations. The company achieved strong financial results, with a 6.9% growth in normalized funds from operations (FFO) per share for the quarter and a 5.9% increase for the entire year, driven by solid core portfolio performance.
Following the earnings report, a Deutsche Bank analyst upgraded Equity LifeStyle Properties Inc. (NYSE:ELS) from Hold to Buy and raised the price target from $66 to $73. Deutsche Bank has shifted its strategy in the residential REIT sector for 2025, focusing on subsectors and stocks less affected by ongoing supply challenges. As part of this strategy, the bank adopted an overweight position on manufactured housing due to its perceived stability, which contributed to the upgrade.
13. Ingredion Inc. (NYSE:INGR)
Beta: 0.75
Number of Hedge Fund Holders: 36
Ingredion Inc. (NYSE:INGR) is a global provider of ingredient solutions, specializing in starches, sweeteners, and plant-based proteins for various applications across the food, beverage, and industrial sectors. The company supports industries such as food processing, pharmaceuticals, and personal care by offering ingredients that enhance texture, taste, and nutritional value.
Ingredion Inc. (NYSE:INGR) converts plant-based materials into high-value ingredients for industries like food, beverages, animal nutrition, and industrial applications. While the market is large, growth remains moderate, driven by changing consumer preferences and dietary trends. From 2021 to 2024, sales grew at a CAGR of over 3%, with a similar outlook for 2025. In 2024, the company generated $1.44 billion in operating cash flow, reinforcing its financial strength and long-term growth potential.
Analyst sentiments on Ingredion (NYSE:INGR) are broadly positive, with a median 1-year upside potential of 20%. However, following its Q4 results, some analysts took a more cautious stance. BMO Capital, for instance, lowered its price target from $147 to $133 while maintaining a Market Perform rating. Although the company’s EPS guidance mid-point aligned with consensus, segment-level performance was underwhelming, with operating income growth projected in the mid-single digits. Despite this, the analyst remains constructive on long-term fundamentals, citing volume recovery, cost-saving initiatives, and growth projects as key strengths.
Similarly, an Oppenheimer analyst trimmed its price target from $178 to $167 but reiterated an Outperform rating. As per him, while Q4 results were strong, the 2025 outlook fell slightly short of expectations, and tempered investor sentiment due to a broad range of possible outcomes. However, the analyst remained optimistic, noting that high pre-report expectations had already been priced in.
12. Royalty Pharma plc (NASDAQ:RPRX)
Beta: 0.47
Number of Hedge Fund Holders: 39
Royalty Pharma plc (NASDAQ:RPRX) has a slightly different model as compared to pharma peers. The company buys biopharmaceutical royalties, offering funding to life sciences companies and research institutions in exchange for future royalty payments. Its portfolio includes interests in blockbuster drugs across various therapeutic areas, including oncology, rare diseases, and neurology.
In late January, BofA Securities analyst Jason Gerberry reaffirmed a Buy rating on Royalty Pharma plc (NASDAQ:RPRX) and raised the price target from $38 to $41. He cited the internalization of RP Management LLC (RP) and upcoming financial catalysts as key drivers. RP internalization simplifies financial reporting, aligns management with shareholders, and boosts portfolio cash flow, despite potential equity dilution. The analyst also expected major growth opportunities, including the launch of Alyftrek, which could convert many Trikafta therapy patients, and key drug trial results from Novartis and Bristol, potentially accelerating the company’s expansion. In mid-February, Citi analyst Geoff Meacham also reiterated a Buy rating on the shares with a price target of $40, implying a 19% upside.
11. Exelon Corp. (NASDAQ:EXC)
Beta: 0.51
Number of Hedge Fund Holders: 47
Exelon Corp. (NASDAQ:EXC) is the largest regulated utility company in the United States, delivering electricity and natural gas to over 10.5 million customers through its subsidiaries. With a focus on clean energy production, the company operates one of the largest portfolios of renewable and natural gas assets.
In the fourth quarter of 2024, the company reported adjusted operating earnings of $0.64 per share, up from $0.60 per share in the same quarter of the previous year. For the full year, adjusted operating earnings reached $2.50 per share, an increase from $2.38 in 2023. Looking ahead, the company has provided guidance for adjusted operating earnings in 2025 to be between $2.64 and $2.74 per share, reflecting an 8% year-over-year growth.
Exelon Corp. (NASDAQ:EXC) has also raised its planned capital expenditures by 10%, allocating $38 billion over the next four years to improve grid reliability and meet customer needs. This investment is expected to result in a 7.4% growth in the rate base, which represents the assets on which the company generates revenue. Additionally, the company anticipates an operating EPS compounded annual growth rate (CAGR) of 5–7% from 2024 to 2028.
The company’s increased investments and stable, regulated business model position it for growth while maintaining its defensive appeal. Exelon Corp. (NASDAQ:EXC) continues to stand out as a dependable option within the utility sector.
10. The Southern Company (NYSE:SO)
Beta: 0.46
Number of Hedge Fund Holders: 53
The Southern Company (NYSE:SO) is a utility provider serving around nine million customers across the southeastern United States. It leverages a diverse energy portfolio, including natural gas, nuclear, and renewable sources.
On February 21, following the release of the company’s Q4 earnings, a Mizuho analyst raised the price target for The Southern Company (NYSE:SO) from $85 to $90 while maintaining a Neutral rating. The analyst now expects a 7% growth in the rate base, up from the earlier forecast of 6%, driven by the company’s revised capital expenditure plan. However, the rating remained unchanged due to concerns about limited upside potential stemming from valuation.
Despite this, The Southern Company (NYSE:SO) benefits from strong regulatory support and a proven record of consistent dividend payments, making it an attractive option for income-focused investors. The company is dedicated to transitioning toward low-carbon energy while ensuring reliable and affordable services. Additionally, it is responding to increasing demand from data centers, recently securing contracts in two U.S. states for over 1,000 megawatts of energy.
Looking ahead, the company projects an annual average sales growth of about 8% between 2025 and 2029. Its commercial segment, which includes data centers and contributes nearly one-third of total retail electricity sales, is anticipated to grow at an average rate of 18% over the same timeframe, supporting a positive long-term growth outlook.
9. The Clorox Company (NYSE:CLX)
Beta: 0.45
Number of Hedge Fund Holders: 54
The Clorox Company (NYSE:CLX) is a consumer staples company recognized for its extensive portfolio of household cleaning, personal care, and wellness brands. Its products, such as CloroxPro, Pine-Sol, Burt’s Bees, and Glad, benefit from strong brand recognition and customer loyalty.
In Q2 FY 2025, the company reported a 15% decline in net sales, primarily due to the lingering effects of the August 2023 cyberattack and the divestitures of its VMS and Argentina businesses. Despite a modest 80 basis point year-over-year increase in gross margins to 43.8%, adjusted EPS fell 28% to $1.55, though cost-saving measures helped offset some of the impact. The Clorox Company (NYSE:CLX) is targeting to restore its gross margins to peak levels of 44% in 2025 and intends to expand EBIT margins by 25 to 50 basis points annually starting in fiscal year 2026, outlining a clear strategy for financial improvement.
The Clorox Company (NYSE:CLX) is also set to take full ownership of the Glad joint venture by January 2026 through the acquisition of The Procter & Gamble Company (NYSE:PG)’s stake. With benefits flowing in from its cost efficiency efforts in recent quarters, the company revised the FY 2025 outlook and now anticipates a 1%-2% decline in net sales while it raised the lower end of its gross margin improvement forecast to 125-150 basis points from the prior 100-150 basis points. Additionally, adjusted EPS is now projected to be between $6.95 and $7.35, up from the earlier estimate of $6.65 to $6.90.
Overall, The Clorox Company (NYSE:CLX) maintains a resilient business model, a strong portfolio of brands, and steady demand for its household and personal care products. While inflation and supply chain disruptions have pressured margins, the company is focused on price adjustments and cost-saving measures to drive recovery.
8. Duke Energy Corp. (NYSE:DUK)
Beta: 0.47
Number of Hedge Fund Holders: 62
Duke Energy Corp. (NYSE:DUK) is one of the largest utility companies in the United States, providing electricity and natural gas services to more than eight million customers. Its diverse portfolio includes regulated electric utilities, renewable energy projects, and grid modernization initiatives.
The company’s solid financial position, strategic infrastructure investments, and regulated utility operations contribute to consistent cash flows, reinforcing its status as a defensive play in uncertain economic conditions. Corroborating this positive view, a BMO Capital analyst recently increased Duke Energy Corp. (NYSE:DUK)’s price target from $123 to $128 while reiterating an Outperform rating. Following discussions with the company’s management, the analyst remained optimistic about the stock, highlighting the company’s stable regulatory environment and defensive positioning. Additionally, he sees a clear growth trajectory that could support multiple expansion as the company continues to execute on its strategy.
7. Colgate-Palmolive Company (NYSE:CL)
Beta: 0.40
Number of Hedge Fund Holders: 62
Colgate-Palmolive Company (NYSE:CL) is one of the most recognized brands worldwide and a global leader in oral care, personal care, and household products. The company’s portfolio includes well-known brands such as Colgate, Palmolive, and Hill’s Pet Nutrition. With operations spanning over 200 countries, it holds a strong foothold in emerging markets.
In 2024, the company generated $20 billion in net sales, reflecting a 3.3% year-over-year increase and surpassing its strategic target a full year ahead of schedule. This achievement highlights Colgate-Palmolive’s strong sales momentum and effective execution. While net sales declined 0.1% in Q4, organic sales grew by 4.3%. Additionally, the company returned $3.4 billion to shareholders in 2024 through dividends and share repurchases.
In early February, a Raymond James analyst reduced the price target on Colgate-Palmolive Company (NYSE:CL) to $105 from $110 while maintaining an Outperform rating. The analyst expressed a more cautious outlook heading into 2025 due to a larger-than-expected Q4 sales decline but remains positive on the company’s long-term potential. Meanwhile, the impact of new tariffs on imports from Mexico and China is expected to have a minimal effect on annualized EPS, supported by accelerating savings from the company’s Funding the Growth initiative. In a more recent update on March 14, JPMorgan analyst Andrea Teixeira raised the firm’s price target on Colgate-Palmolive Company (NYSE:CL) to $99 from $97 while reiterating an Overweight rating.
6. PepsiCo Inc. (NASDAQ:PEP)
Beta: 0.52
Number of Hedge Fund Holders: 69
Our next pick, PepsiCo Inc. (NASDAQ:PEP) is more than just a soft drink giant, it is a global food and beverage powerhouse. It has a diverse portfolio of brands, including Pepsi, Mountain Dew, Lay’s, Gatorade, and Quaker. With operations in over 200 countries, the company benefits from strong brand equity and a balanced revenue mix between beverages and snack foods.
On March 17, PepsiCo Inc. (NASDAQ:PEP) announced the acquisition of poppi, a rapidly growing prebiotic soda brand, for $1.95 billion. poppi is a modern functional soda that blends prebiotics, fruit juice, apple cider vinegar, and reduced sugar, catering to both cultural and wellness trends. While the acquisition aligns strategically with PepsiCo’s long-term goals, investors expressed concerns over the high valuation paid and the brand’s profitability.
Following the acquisition, Barclays analyst Lauren Lieberman downgraded PepsiCo (NASDAQ:PEP) from Overweight to Equal Weight, cutting the price target from $168 to $156. The downgrade reflects scepticism over the company’s ability to achieve a valuation re-rating, which largely depends on the performance of its U.S. snack division. The analyst sees the turnaround of Frito-Lay North America (FLNA) as a challenging task that could take several quarters to stabilize, particularly amid an uncertain macroeconomic environment. However, the analyst remains optimistic about FLNA’s long-term growth potential, expecting sustainable volume growth of 1.5%.
Despite near-term concerns, the consensus 1-year median price target stands at $164, suggesting a potential 13% upside. With its broad product portfolio and global distribution network, PepsiCo (NASDAQ:PEP) continues to innovate and adapt to evolving consumer preferences, strengthening its leadership in the food and beverage industry.
5. T-Mobile US Inc. (NASDAQ:TMUS)
Beta: 0.64
Number of Hedge Fund Holders: 70
T-Mobile US, Inc. (NASDAQ:TMUS) is a leading telecommunications provider known for its aggressive expansion strategy and customer-centric approach. Following its merger with Sprint, T-Mobile has strengthened its position in the U.S. wireless market, offering competitive pricing and 5G network leadership.
Around March 18, JP Morgan analyst Sebastiano Petti reaffirmed a Buy rating on T-Mobile US (NASDAQ:TMUS) with a price target of $270, citing strong medium-term financial guidance. The company is expected to achieve a 7% compound annual growth rate (CAGR) in EBITDA and an 8% CAGR in free cash flow through 2027, driven by continued gains in postpaid phone market share across key segments, including the Top 100 markets, SMRA, and Enterprise sectors.
The analyst also highlighted T-Mobile’s ambitious capital return program. The company aims to return up to $50 billion by 2027, with $20 billion in flexible spending, thus enhancing the stock’s appeal. He also highlighted the company’s ability to sustain substantial postpaid phone net additions, with stable expectations for 2025, reinforcing his bullish outlook on the stock.
4. The Procter & Gamble Company (NYSE:PG)
Beta: 0.41
Number of Hedge Fund Holders: 79
The Procter & Gamble Company (NYSE:PG) is a global consumer goods leader with a vast portfolio of brands, including Tide, Pampers, Gillette, and Head & Shoulders, which are well known and trusted by millions of households worldwide. It operates in over 180 countries and benefits from strong brand recognition and consumer loyalty.
In a move that supports the investment case for the company, Erste Group analyst Stephan Lingnau upgraded the company’s rating to Buy from Hold, in a report on March 17. The analyst expects the company to exceed its guided EPS growth rate, and believes the stock is attractively valued compared to the sector.
Earlier on February 20, Wells Fargo analyst Christopher Carey had also reaffirmed his Buy rating on The Procter & Gamble Company (NYSE:PG) with a price target of $185. While short-term inventory fluctuations remain a factor, the analyst highlighted the strength of U.S. consumer demand and the company’s ability to keep its EPS within the range of its FY 2025 guidance, assuming a recovery in inventory re-orders.
Looking ahead to FY 2026, the Wells Fargo analyst highlighted that The Procter & Gamble Company (NYSE:PG) has given a positive outlook, with the potential to align with its growth strategy. This optimism was backed by strong global trends and market share gains across key regions. Additionally, the analyst believes the company can manage external factors such as foreign exchange and commodity prices well which further supported the Buy rating.
3. The Coca-Cola Company (NYSE:KO)
Beta: 0.58
Number of Hedge Fund Holders: 81
The Coca-Cola Company (NYSE:KO) is a global beverage company with a portfolio of over 200 brands, including Coca-Cola, Sprite, Fanta, and Minute Maid. The company has a strong distribution network spanning over 200 countries with which it generates consistent revenue from its diverse range of carbonated soft drinks, juices, and bottled water. It is consistently ranked among the top most valuable brands worldwide.
In a March 19 report, TD Cowen analyst Robert Moskow reiterated his Buy rating on The Coca-Cola Company (NYSE:KO) with a price target of $78. The analyst attributed the company’s competitive strength to its strong relationships with bottlers and its effective marketing and procurement strategies. Although there are challenges like weakening consumer confidence and potential regulatory shifts in the U.S., he highlighted company’s “all-weather strategy” and resilient bottling system that have helped it navigate market volatility over the past five years.
Additionally, the analyst pointed to management’s effective handling of the current consumer landscape, and ability to maintain an organic sales growth forecast of 6% for 2025. The company’s focus on digitalization and improved communication with bottlers has enhanced operational efficiency which further reinforces the positive outlook on the company.
2. NextEra Energy Inc. (NYSE:NEE)
Beta: 0.59
Number of Hedge Fund Holders: 84
NextEra Energy Inc. (NYSE:NEE) is one of the largest electric power and energy infrastructure companies in North America and a leader in renewable energy generation. The company’s subsidiary, Florida Power & Light (FPL), is the largest utility in the state of Florida and serves regulated electric services. On the other hand, its NextEra Energy Resources (NEER) business is the world’s largest generator of renewable energy from the wind and sun, as well as a world leader in battery storage capacity.
On March 20, Morgan Stanley analyst David Arcaro reaffirmed his Buy rating on NextEra Energy Inc. (NYSE:NEE) with a price target of $95. He highlighted the company’s strong position in the energy sector, backed by its expertise in renewables, gas, and nuclear power, as well as a robust development pipeline. NextEra’s focus on renewable energy was also highlighted as it aligns with the industry’s transition toward sustainable solutions, which are scalable as well as cost-effective.
The analyst further noted that the company leverages advanced technology and data analytics to strengthen its competitive edge. While gas capacity constraints exist, the company’s diverse asset portfolio and expertise in transmission development enable it to meet the growing power needs of large-scale customers, including data centers. In addition, the company’s inclination towards innovation and its strong market presence supported the analyst’s positive outlook.
1. Merck & Co. Inc. (NYSE:MRK)
Beta: 0.35
Number of Hedge Fund Holders: 91
Merck & Co. Inc. (NYSE:MRK) is a global pharmaceutical company known for its innovations in vaccines, oncology, and infectious diseases as well as animal health products. The company’s blockbuster drugs, including Keytruda and Gardasil, contribute significantly to its revenue growth.
DBS analyst Nico Chen had reaffirmed a Buy rating on Merck & Co. Inc. (NYSE:MRK) in a mid-February report. He kept his price target at $100 and cited strong growth driven by Keytruda as a reason for his positive outlook. The analyst said that this blockbuster oncology drug has significantly boosted revenue and continues to expand globally.
Another key factor, in his view, was the promising development of sac-TMT, an antibody-drug conjugate for advanced non-small cell lung cancer, which received ‘Breakthrough Therapy Designation’ from the FDA. This could accelerate its market entry and strengthen the company’s valuation. Additionally, the analyst thinks that Merck’s financial outlook remains strong, with expected net income growth and lower patent expiry risks compared to peers.
While we acknowledge the potential of MRK to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
